LY2495655
Phase 2Small molecule
Eli LillyLY2495655 is one of 45 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
Byetta
AstraZenecaPreclinical
MS Contin
Merck & Co.Preclinical
Medrol
PfizerPreclinical
LY2495655
Eli LillyPhase 2
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Thiazolidinediones
SanofiPreclinical
Sulfonylureas
Eli LillyPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Total Hip Replacement1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY2495655. EMBL-EBI & Wellcome Sanger Institute.
- [4]